Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Tuesday morning, Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, Wedbush reiterated an outperform rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Friday, March 22nd.

Compass Therapeutics Stock Down 1.3 %

NASDAQ CMPX opened at $1.47 on Tuesday. Compass Therapeutics has a 52 week low of $1.15 and a 52 week high of $3.62. The stock has a market capitalization of $202.26 million, a PE ratio of -4.32 and a beta of 0.78. The firm has a 50 day moving average of $1.84 and a two-hundred day moving average of $1.72.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). On average, equities research analysts expect that Compass Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in Compass Therapeutics by 577.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock valued at $26,000 after purchasing an additional 6,695 shares during the last quarter. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $35,000. Alliancebernstein L.P. purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $36,000. UBS Group AG raised its position in Compass Therapeutics by 63.5% in the 4th quarter. UBS Group AG now owns 11,819 shares of the company’s stock valued at $59,000 after purchasing an additional 4,591 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $38,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.